PDS Biotechnology (PDSB) Depreciation & Amortization (CF) (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Depreciation & Amortization (CF) came in at $5459.0 in Q4 2025, little changed YoY from $5458.0 in Q4 2024, and little changed on a QoQ basis from $5459.0 in Q3 2025.
PDS Biotechnology (PDSB) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $5459.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) changed 0.02% year-over-year to $5459.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21836.0 (up 3.43% YoY) and the FY2025 annual result came in at $21836.0, up 3.43% from the prior year.
- Depreciation & Amortization (CF) steadied at $5459.0 in Q4 2025, from $5459.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $5460.0 in Q3 2024 to a low of $86.0 in Q1 2022.
- A 5-year average of $3867.6 and a median of $4735.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 95.38% — and 2023, when it jumped 3568.6%.
- Tracing PDSB's Depreciation & Amortization (CF) over 5 years: stood at $951.0 in 2021, then plunged by 90.96% to $86.0 in 2022, then soared by 5405.81% to $4735.0 in 2023, then increased by 15.27% to $5458.0 in 2024, then increased by 0.02% to $5459.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $5459.0 (Q4 2025), $5459.0 (Q3 2025), and $5459.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,459.00 |
| Dec 31, 2025 | 5,459.00 |
| Sep 30, 2025 | 5,459.00 |
| Sep 30, 2025 | 5,459.00 |
| Jun 30, 2025 | 5,459.00 |
| Jun 30, 2025 | 5,459.00 |
| Mar 31, 2025 | 5,459.00 |
| Mar 31, 2025 | 5,459.00 |
| Dec 31, 2024 | 5,458.00 |
| Dec 31, 2024 | 5,458.00 |
| Sep 30, 2024 | 5,460.00 |
| Sep 30, 2024 | 5,460.00 |
| Jun 30, 2024 | 5,459.00 |
| Jun 30, 2024 | 5,459.00 |
| Mar 31, 2024 | 4,735.00 |
| Mar 31, 2024 | 4,735.00 |
| Dec 31, 2023 | 4,735.00 |
| Dec 31, 2023 | 4,735.00 |
| Sep 30, 2023 | 4,733.00 |
| Sep 30, 2023 | 4,733.00 |